FOSTER CITY, Calif., February 25, 2026--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced the presentation of new Phase 3 ARTISTRY-1 and ARTISTRY-2 trial data at CROI 2026 showing ...

So far, in a Phase I trial, incidents of CRS have been low grade on VIR-5500, and 14 of 17 evaluable patients saw more than a 50 percent decrease in PSA levels.

A new, daily oral tablet that combines two current HIV treatment medications, bictegravir and lenacapavir (BIC/LEN), could ...

DOR/ISL is currently at the pre-registration stage of development in the US and is expected to launch in this market in 2026, ...

Merck , known as MSD outside of the United States and Canada, today announced the presentation of results from three pivotal Phase 3 trials evaluating the investigational, once-daily, oral, two-drug ...

Children with HIV on dolutegravir (Tivicay)-based antiretroviral therapy (ART) can safely receive the standard prophylactic ...

Antiretroviral therapies (ART) against HIV have been in use for more than 30 years and have enabled people living with HIV to maintain undetectable viral levels. Many of them are aging in good health.

Immunocore reports fourth quarter and full year 2025 financial results and provides a business update KIMMTRAK (tebentafusp-tebn) Q4 net sales ...

Researchers from Brown University and the University of Rochester will lead a multi-institution project to test whether ...

A new study has overcome a long-standing challenge-how to isolate and study elusive HIV-infected cells called authentic reservoir clones (ARCs) that evade the immune system, making the disease ...

One-third of children with HIV who received very early ART had no detectable virus in their body for at least 12 weeks after stopping treatment, according to study findings. It was another sign that ...

GLP-1 receptor agonists improve glycemic control and weight while reducing cardiovascular events, with tolerability limited by gastrointestinal adverse effects requiring gradual dose escalation.